{"success":true,"data":{"pressRelease":{"id":"171816","rtpr_id":"nGNX5M0l89-20261016","ticker":"NNOX","exchange":"NASDAQ","all_tickers":["NNOX"],"title":"Nanox Provides Business Update and Furnishes Certain Preliminary Unaudited Financial Data for Third Quarter Ended September 30, 2026","author":"Globe Newswire","published_at":"2026-10-16T20:05:00.179Z","article_body":"PETACH TIKVA, Israel, Oct. 16, 2026 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD\n(NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical\nimaging technology company, today provided a brief business update and\nfurnished certain preliminary unaudited financial data for the third quarter\nended September 30, 2026. The preliminary figures are estimates based on\ncurrently available information, are preliminary and unaudited, and are\nsubject to change upon completion of the Company’s financial close process,\nfinal adjustments, management review and other internal procedures, and review\nby its independent auditors. The Company’s final reported unaudited\nfinancial results for the third quarter of 2026 may differ materially from the\npreliminary figures and will be reported in a subsequent press release at a\nlater date.\n\nBusiness Update\n\nNanox.AI: Nanox AI enters into a distribution agreement with Technologic\ns.r.l., an Affiliate of Tecnologie Avanzate, to commercialize Nanox.AI’s\nBone Solution in Italy. Collaboration leverages Tecnologie Avanzate’s\nexperience, established healthcare industry relationships, and expertise in\nthe Italian market.\n\nTIME Best Inventions Recognition: Nanox selected as one of TIME’s Best\nInventions of 2026 for its Nanox.ARC X. Nanox.ARC X recognized among the\n“world’s most groundbreaking innovations” and for its approach to making\nadvanced medical imaging more accessible.\n\nPreliminary Financial Data for the Three Months Ended September 30, 2026\n\nCautionary Note Regarding Preliminary Financial Data\n\nThe preliminary financial data set forth below represents the Company’s\ncurrent estimates based on information available as of the date of this press\nrelease. These estimates are preliminary and unaudited, have been prepared by\nand are the responsibility of the Company’s management, and are subject to\nthe completion of the Company’s financial closing procedures, final\nadjustments, management review and other internal review procedures, and other\ndevelopments that may arise between now and the time the financial results are\nfinalized.\n\nIn addition, the Company’s independent registered public accounting firm has\nnot audited, reviewed, compiled, or applied agreed-upon procedures with\nrespect to the preliminary financial results. Accordingly, it does not express\nan opinion or any other form of assurance with respect thereto.\n\nPreliminary Revenue Data\n\nOn a preliminary unaudited basis, the Company expects its revenue to be\napproximately $4.3 to $4.4 million for the three months ended September 30,\n2026 (the “Reported Period”), compared to $3.4 million for the\ncorresponding three-month period in 2025 (the “Comparable Period”). During\nthe Reported Period, the Company generated revenue through teleradiology\nservices, the sale and deployment of its imaging systems and its AI and\nsoftware solutions.\n\nThe Company’s revenue from teleradiology services for the Reported Period\nwas approximately $3.1 million, compared to revenue of $3.1 million in the\nComparable Period.\n\nDuring the Reported Period, the Company generated revenue through the sale and\ndeployment of its imaging systems and OEM services which amounted to\napproximately $0.3 million for the Reported Period, compared to revenue of\n$0.2 million in the Comparable Period. This increase in revenue is related\nmainly to an additional Nanox.ARC CapEx agreement.\n\nThe Company’s revenue from its AI and software solutions for the Reported\nPeriod was $1.0 million, compared to revenue of $0.1 million in the Comparable\nPeriod. This increase in revenue is related mainly to the consolidation of\nVaso Healthcare IT Inc. (now Nanox Health IT Inc.) by the Company.\n\nPreliminary Balance Sheet Data\n\nOn a preliminary unaudited basis, the Company expects its cash, cash\nequivalents, short-term deposits and long-term restricted deposits to be\napproximately $26.0 million as of September 30, 2026, as compared to $60.0\nmillion as of December 31, 2025.\n\nThe Company expects to continue to incur significant costs related to its\nongoing operations. Management expects that the Company’s cash and cash\nequivalents, and deposits, as of September 30, 2026, are not sufficient to\nsupport the Company’s operations under its current operating plans for at\nleast one year from the date of this press release. These factors raise\nsubstantial doubt as to the Company’s ability to continue as a going\nconcern. If the Company is unable to raise additional funds when needed, it\nmay be required to delay, reduce or eliminate its product development or\nfuture commercialization efforts, or grant rights to develop and market\nproducts that it would otherwise prefer to develop and market itself.\n\nAbout Nanox\n\nNanox (NASDAQ: NNOX) is focused on driving the world’s transition to\npreventive health care by delivering an integrated, end-to-end medical imaging\nand healthcare services platform.\n\nNanox combines affordable imaging hardware, advanced AI-based solutions,\ncloud-based software, access to remote radiology, health IT solutions, and a\nmarketplace to enable earlier detection, improved clinical efficiency, and\nbroader access to care.\n\nNanox’s vision is to expand the reach of medical imaging both within and\nbeyond traditional hospital settings by providing a seamless solution from\nscan to interpretation and beyond. By leveraging proprietary digital X-ray\ntechnology, AI-driven analytics, and a clinically driven approach, Nanox aims\nto enhance the efficiency of routine imaging workflows, support early\ndetection of disease, and improve patient outcomes.\n\nThe Nanox ecosystem includes Nanox.ARC, a cost-effective, 3D multi-source\ndigital tomosynthesis imaging system designed for ease of use and scalability;\nNanox.AI, a suite of AI-based algorithms that augment the interpretation of\nroutine CT imaging to identify early signs often associated with chronic\ndisease; Nanox.CLOUD, a cloud-based platform for secure data management,\nstorage, and advanced imaging analytics; Nanox.MARKETPLACE and USARAD\nHoldings, which provides access to remote radiology and cardiology experts and\ncomprehensive teleradiology services; and Nanox Health IT combines deep\nhealthcare IT expertise with leading technology partners to deliver RIS, PACS,\nAI, dictation, and secure infrastructure solutions that streamline workflows\nand support safer, more efficient care delivery.\n\nBy integrating imaging technology, AI, cloud infrastructure, clinical\nexpertise, a marketplace, and health information technology, Nanox seeks to\nlower barriers to adoption, improve utilization, and advance preventive care\nworldwide. For more information, please visit https://www.nanox.vision.\n\nForward-Looking Statements\n\nThis press release contains forward-looking statements that are subject to\nrisks and uncertainties. All statements that are not historical facts\ncontained in this press release are forward-looking statements preliminary\nunaudited revenue, revenue by category, cash, cash equivalents, deposits and\nrestricted deposits; expected future operating costs, liquidity, going concern\nmatters. Factors that could cause actual results to differ materially from\nthose currently anticipated include: risks related to (i) the preliminary and\nunaudited nature of the financial data included in this press release, the\ncompletion of the Company’s financial closing procedures, final adjustments,\nmanagement review and other internal review procedures and the Company’s\nongoing evaluation of potential impairment charges; (ii) Nanox’s ability to\ncomplete development of the Nanox System; (ii) Nanox’s history of recurring\nlosses and negative cash flows from operating activities, significant future\ncommitments, the uncertainty regarding the adequacy of Nanox’s liquidity to\npursue its complete business objectives, substantial doubt regarding its\nability to continue as a going concern and its ability to raise additional\ncapital on acceptable terms or at all; (iii) Nanox’s ability to complete\ndevelopment of the Nanox System and successfully demonstrate the feasibility\nof its technology for commercial applications; (iv) Nanox’s expectations\nregarding the necessity of, timing of filing for, and receipt and maintenance\nof, regulatory clearances or approvals regarding its technology, the Nanox.ARC\nand Nanox.CLOUD from regulatory agencies worldwide and its ongoing compliance\nwith applicable quality standards and regulatory requirements; (v) Nanox’s\nability to complete installations, commercially activate sites, support\nphysician outreach and generate anticipated revenue from its imaging systems,\nAI and software solutions and teleradiology services; (vi) Nanox’s ability\nto realize the anticipated benefits of acquisitions, distribution arrangements\nand other commercial agreements, including annual minimum purchase\ncommitments, which may be affected by, among other things, competition,\ncustomer adoption, brand recognition, integration risks, the ability of\nacquired businesses to grow and manage growth profitably and retain key\nemployees; (vii) Nanox’s ability to enter into and maintain commercially\nreasonable arrangements with third-party manufacturers and suppliers to\nmanufacture the Nanox.ARC; (viii) market acceptance of the Nanox System and\nthe proposed pay-per-scan business model; (ix) Nanox’s expectations\nregarding collaborations with third parties and their potential benefits; (x)\nNanox’s ability to conduct business globally; (xi) changes in global,\npolitical, economic, business, competitive, market and regulatory forces;\n(xii) risks related to the current conflict between the United States (and, at\ntimes, Israel), on the one hand, and Iran and its proxies, on the other hand,\nand any adverse impact of that conflict on Israel; and (xiii) risks related to\nlitigation, which may result in significant liability and damage to the\nCompany’s reputation.\n\nFor a discussion of other risks and uncertainties, and other important\nfactors, any of which could cause Nanox’s actual results to differ from\nthose contained in forward-looking statements or from the preliminary\nunaudited financial data furnished in this press release, please see the\nsection titled “Risk Factors” in Nanox’s Annual Report on Form 20-F for\nthe year ended December 31, 2025, filed with the U.S. Securities and Exchange\nCommission (the “SEC”) on April 30, 2026, and in subsequent documents\nfiled with, or furnished to, the SEC by Nanox. The reader should not place\nundue reliance on any forward-looking statements or preliminary unaudited\nfinancial data included in this press release. Except as required by law,\nNanox undertakes no obligation to update publicly any forward-looking\nstatements or preliminary unaudited financial data after the date of this\npress release to conform these statements or data to actual results or to\nchanges in Nanox’s expectations.\n\nContacts\n\nMedia Contact:\nBen Shannon\nICR Healthcare\nNanoxPR@icrinc.com\n\nInvestor Contact:\nMike Cavanaugh\nICR Healthcare\nmike.cavanaugh@icrhealthcare.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/57c1ffd6-84b3-46b9-b9b3-76666e6ba5a2)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX5M0l89-20261016","title":"Nanox Provides Business Update and Furnishes Certain Preliminary Unaudited Financial Data for Third Quarter Ended September 30, 2026","author":"Globe Newswire","ticker":"NNOX","created":"2026-10-16T20:05:00.179Z","tickers":["NNOX"],"exchange":"NASDAQ","article_body":"PETACH TIKVA, Israel, Oct. 16, 2026 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD\n(NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical\nimaging technology company, today provided a brief business update and\nfurnished certain preliminary unaudited financial data for the third quarter\nended September 30, 2026. The preliminary figures are estimates based on\ncurrently available information, are preliminary and unaudited, and are\nsubject to change upon completion of the Company’s financial close process,\nfinal adjustments, management review and other internal procedures, and review\nby its independent auditors. The Company’s final reported unaudited\nfinancial results for the third quarter of 2026 may differ materially from the\npreliminary figures and will be reported in a subsequent press release at a\nlater date.\n\nBusiness Update\n\nNanox.AI: Nanox AI enters into a distribution agreement with Technologic\ns.r.l., an Affiliate of Tecnologie Avanzate, to commercialize Nanox.AI’s\nBone Solution in Italy. Collaboration leverages Tecnologie Avanzate’s\nexperience, established healthcare industry relationships, and expertise in\nthe Italian market.\n\nTIME Best Inventions Recognition: Nanox selected as one of TIME’s Best\nInventions of 2026 for its Nanox.ARC X. Nanox.ARC X recognized among the\n“world’s most groundbreaking innovations” and for its approach to making\nadvanced medical imaging more accessible.\n\nPreliminary Financial Data for the Three Months Ended September 30, 2026\n\nCautionary Note Regarding Preliminary Financial Data\n\nThe preliminary financial data set forth below represents the Company’s\ncurrent estimates based on information available as of the date of this press\nrelease. These estimates are preliminary and unaudited, have been prepared by\nand are the responsibility of the Company’s management, and are subject to\nthe completion of the Company’s financial closing procedures, final\nadjustments, management review and other internal review procedures, and other\ndevelopments that may arise between now and the time the financial results are\nfinalized.\n\nIn addition, the Company’s independent registered public accounting firm has\nnot audited, reviewed, compiled, or applied agreed-upon procedures with\nrespect to the preliminary financial results. Accordingly, it does not express\nan opinion or any other form of assurance with respect thereto.\n\nPreliminary Revenue Data\n\nOn a preliminary unaudited basis, the Company expects its revenue to be\napproximately $4.3 to $4.4 million for the three months ended September 30,\n2026 (the “Reported Period”), compared to $3.4 million for the\ncorresponding three-month period in 2025 (the “Comparable Period”). During\nthe Reported Period, the Company generated revenue through teleradiology\nservices, the sale and deployment of its imaging systems and its AI and\nsoftware solutions.\n\nThe Company’s revenue from teleradiology services for the Reported Period\nwas approximately $3.1 million, compared to revenue of $3.1 million in the\nComparable Period.\n\nDuring the Reported Period, the Company generated revenue through the sale and\ndeployment of its imaging systems and OEM services which amounted to\napproximately $0.3 million for the Reported Period, compared to revenue of\n$0.2 million in the Comparable Period. This increase in revenue is related\nmainly to an additional Nanox.ARC CapEx agreement.\n\nThe Company’s revenue from its AI and software solutions for the Reported\nPeriod was $1.0 million, compared to revenue of $0.1 million in the Comparable\nPeriod. This increase in revenue is related mainly to the consolidation of\nVaso Healthcare IT Inc. (now Nanox Health IT Inc.) by the Company.\n\nPreliminary Balance Sheet Data\n\nOn a preliminary unaudited basis, the Company expects its cash, cash\nequivalents, short-term deposits and long-term restricted deposits to be\napproximately $26.0 million as of September 30, 2026, as compared to $60.0\nmillion as of December 31, 2025.\n\nThe Company expects to continue to incur significant costs related to its\nongoing operations. Management expects that the Company’s cash and cash\nequivalents, and deposits, as of September 30, 2026, are not sufficient to\nsupport the Company’s operations under its current operating plans for at\nleast one year from the date of this press release. These factors raise\nsubstantial doubt as to the Company’s ability to continue as a going\nconcern. If the Company is unable to raise additional funds when needed, it\nmay be required to delay, reduce or eliminate its product development or\nfuture commercialization efforts, or grant rights to develop and market\nproducts that it would otherwise prefer to develop and market itself.\n\nAbout Nanox\n\nNanox (NASDAQ: NNOX) is focused on driving the world’s transition to\npreventive health care by delivering an integrated, end-to-end medical imaging\nand healthcare services platform.\n\nNanox combines affordable imaging hardware, advanced AI-based solutions,\ncloud-based software, access to remote radiology, health IT solutions, and a\nmarketplace to enable earlier detection, improved clinical efficiency, and\nbroader access to care.\n\nNanox’s vision is to expand the reach of medical imaging both within and\nbeyond traditional hospital settings by providing a seamless solution from\nscan to interpretation and beyond. By leveraging proprietary digital X-ray\ntechnology, AI-driven analytics, and a clinically driven approach, Nanox aims\nto enhance the efficiency of routine imaging workflows, support early\ndetection of disease, and improve patient outcomes.\n\nThe Nanox ecosystem includes Nanox.ARC, a cost-effective, 3D multi-source\ndigital tomosynthesis imaging system designed for ease of use and scalability;\nNanox.AI, a suite of AI-based algorithms that augment the interpretation of\nroutine CT imaging to identify early signs often associated with chronic\ndisease; Nanox.CLOUD, a cloud-based platform for secure data management,\nstorage, and advanced imaging analytics; Nanox.MARKETPLACE and USARAD\nHoldings, which provides access to remote radiology and cardiology experts and\ncomprehensive teleradiology services; and Nanox Health IT combines deep\nhealthcare IT expertise with leading technology partners to deliver RIS, PACS,\nAI, dictation, and secure infrastructure solutions that streamline workflows\nand support safer, more efficient care delivery.\n\nBy integrating imaging technology, AI, cloud infrastructure, clinical\nexpertise, a marketplace, and health information technology, Nanox seeks to\nlower barriers to adoption, improve utilization, and advance preventive care\nworldwide. For more information, please visit https://www.nanox.vision.\n\nForward-Looking Statements\n\nThis press release contains forward-looking statements that are subject to\nrisks and uncertainties. All statements that are not historical facts\ncontained in this press release are forward-looking statements preliminary\nunaudited revenue, revenue by category, cash, cash equivalents, deposits and\nrestricted deposits; expected future operating costs, liquidity, going concern\nmatters. Factors that could cause actual results to differ materially from\nthose currently anticipated include: risks related to (i) the preliminary and\nunaudited nature of the financial data included in this press release, the\ncompletion of the Company’s financial closing procedures, final adjustments,\nmanagement review and other internal review procedures and the Company’s\nongoing evaluation of potential impairment charges; (ii) Nanox’s ability to\ncomplete development of the Nanox System; (ii) Nanox’s history of recurring\nlosses and negative cash flows from operating activities, significant future\ncommitments, the uncertainty regarding the adequacy of Nanox’s liquidity to\npursue its complete business objectives, substantial doubt regarding its\nability to continue as a going concern and its ability to raise additional\ncapital on acceptable terms or at all; (iii) Nanox’s ability to complete\ndevelopment of the Nanox System and successfully demonstrate the feasibility\nof its technology for commercial applications; (iv) Nanox’s expectations\nregarding the necessity of, timing of filing for, and receipt and maintenance\nof, regulatory clearances or approvals regarding its technology, the Nanox.ARC\nand Nanox.CLOUD from regulatory agencies worldwide and its ongoing compliance\nwith applicable quality standards and regulatory requirements; (v) Nanox’s\nability to complete installations, commercially activate sites, support\nphysician outreach and generate anticipated revenue from its imaging systems,\nAI and software solutions and teleradiology services; (vi) Nanox’s ability\nto realize the anticipated benefits of acquisitions, distribution arrangements\nand other commercial agreements, including annual minimum purchase\ncommitments, which may be affected by, among other things, competition,\ncustomer adoption, brand recognition, integration risks, the ability of\nacquired businesses to grow and manage growth profitably and retain key\nemployees; (vii) Nanox’s ability to enter into and maintain commercially\nreasonable arrangements with third-party manufacturers and suppliers to\nmanufacture the Nanox.ARC; (viii) market acceptance of the Nanox System and\nthe proposed pay-per-scan business model; (ix) Nanox’s expectations\nregarding collaborations with third parties and their potential benefits; (x)\nNanox’s ability to conduct business globally; (xi) changes in global,\npolitical, economic, business, competitive, market and regulatory forces;\n(xii) risks related to the current conflict between the United States (and, at\ntimes, Israel), on the one hand, and Iran and its proxies, on the other hand,\nand any adverse impact of that conflict on Israel; and (xiii) risks related to\nlitigation, which may result in significant liability and damage to the\nCompany’s reputation.\n\nFor a discussion of other risks and uncertainties, and other important\nfactors, any of which could cause Nanox’s actual results to differ from\nthose contained in forward-looking statements or from the preliminary\nunaudited financial data furnished in this press release, please see the\nsection titled “Risk Factors” in Nanox’s Annual Report on Form 20-F for\nthe year ended December 31, 2025, filed with the U.S. Securities and Exchange\nCommission (the “SEC”) on April 30, 2026, and in subsequent documents\nfiled with, or furnished to, the SEC by Nanox. The reader should not place\nundue reliance on any forward-looking statements or preliminary unaudited\nfinancial data included in this press release. Except as required by law,\nNanox undertakes no obligation to update publicly any forward-looking\nstatements or preliminary unaudited financial data after the date of this\npress release to conform these statements or data to actual results or to\nchanges in Nanox’s expectations.\n\nContacts\n\nMedia Contact:\nBen Shannon\nICR Healthcare\nNanoxPR@icrinc.com\n\nInvestor Contact:\nMike Cavanaugh\nICR Healthcare\nmike.cavanaugh@icrhealthcare.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/57c1ffd6-84b3-46b9-b9b3-76666e6ba5a2)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-16T20:05:00.219388752Z","server_sent_at_ms":1792181100219},"received_at":"2026-10-16T20:05:00.327Z","source_url":null},"analysis":{"id":"159972","press_release_id":"171816","analysis_json":{"industry":{"label":"Health Care Equipment & Supplies","sector":"Health Care"},"redFlags":["going-concern warning: liquidity insufficient for at least one year of operations","cash burn: $26M remaining vs $60M at Dec 31, 2025 — dilutive capital raise likely","preliminary figures unaudited and subject to potential impairment charges"],"eventType":"earnings","narrative":"Nanox furnished preliminary unaudited Q3 2026 revenue of approximately $4.3-4.4 million, up from $3.4 million a year earlier, with AI/software revenue jumping to $1.0 million from $0.1 million.\n\nThe more consequential disclosure is liquidity: cash, deposits and restricted deposits fell to roughly $26 million from $60 million at year-end 2025, and management states these funds are not sufficient to support operations under current plans for at least one year, raising substantial going-concern doubt.\n\nSeparately, Nanox.AI signed a distribution agreement to commercialize its Bone Solution in Italy, and the Nanox.ARC X was named to TIME's Best Inventions of 2026.","sentiment":"bearish","agentHooks":{"shouldPost":true,"suggestedAngle":"Modest revenue growth overshadowed by going-concern doubt and a ~$34M cash drawdown — dilution risk front and center."},"keyFigures":{"revenue":"$4.3 to $4.4 million","guidance":"","revenueYoy":"approximately 27% (from $3.4 million)","customDimensions":{"going_concern":true,"ai_software_revenue":"$1.0 million","cash_and_deposits_q3":"$26.0 million","teleradiology_revenue":"$3.1 million","cash_and_deposits_dec_2025":"$60.0 million","imaging_systems_oem_revenue":"$0.3 million"}},"quotedText":"These factors raise substantial doubt as to the Company's ability to continue as a going concern.","namedEntities":{"people":[{"name":"Ben Shannon","role":"Media Contact, ICR Healthcare"},{"name":"Mike Cavanaugh","role":"Investor Contact, ICR Healthcare"}],"products":["Nanox.ARC X","Nanox.AI Bone Solution","Nanox.ARC","Nanox.CLOUD","Nanox.MARKETPLACE","USARAD"],"companies":[{"name":"NANO-X IMAGING LTD","ticker":"NNOX","relationship":"filer"},{"name":"Technologic s.r.l.","relationship":"distribution partner"},{"name":"Tecnologie Avanzate","relationship":"partner affiliate"},{"name":"Vaso Healthcare IT Inc. (now Nanox Health IT Inc.)","relationship":"consolidated subsidiary"}],"dollarAmounts":[{"amount":"$4.3 to $4.4 million","context":"preliminary Q3 2026 revenue"},{"amount":"$3.4 million","context":"Q3 2025 comparable revenue"},{"amount":"$3.1 million","context":"teleradiology revenue, flat YoY"},{"amount":"$0.3 million","context":"imaging systems and OEM revenue in Q3 2026"},{"amount":"$1.0 million","context":"AI and software revenue in Q3 2026"},{"amount":"$26.0 million","context":"preliminary cash, deposits and restricted deposits as of Sept 30, 2026"},{"amount":"$60.0 million","context":"cash and deposits as of Dec 31, 2025"}]},"materialImpact":{"score":4,"reasoning":"While preliminary Q3 revenue grew ~27% YoY to $4.3-4.4M, the release discloses a going-concern warning: cash fell to ~$26M from $60M and management states liquidity is insufficient to fund operations for at least one year, implying a likely capital raise."},"tickerRelevance":{"others":[],"primary":"NNOX"},"globalImportance":45,"audienceRelevance":45,"eventTypeSecondary":["operations_update"],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"going-concern disclosure with preliminary revenue","issuerAuthored":true,"retailFavoriteBoost":"NNOX has an elevated retail following"}},"event_type":"earnings","event_type_secondary":["operations_update"],"sentiment":"bearish","material_impact_score":4,"narrative":"Nanox furnished preliminary unaudited Q3 2026 revenue of approximately $4.3-4.4 million, up from $3.4 million a year earlier, with AI/software revenue jumping to $1.0 million from $0.1 million.\n\nThe more consequential disclosure is liquidity: cash, deposits and restricted deposits fell to roughly $26 million from $60 million at year-end 2025, and management states these funds are not sufficient to support operations under current plans for at least one year, raising substantial going-concern doubt.\n\nSeparately, Nanox.AI signed a distribution agreement to commercialize its Bone Solution in Italy, and the Nanox.ARC X was named to TIME's Best Inventions of 2026.","key_figures":{"revenue":"$4.3 to $4.4 million","guidance":"","revenueYoy":"approximately 27% (from $3.4 million)","customDimensions":{"going_concern":true,"ai_software_revenue":"$1.0 million","cash_and_deposits_q3":"$26.0 million","teleradiology_revenue":"$3.1 million","cash_and_deposits_dec_2025":"$60.0 million","imaging_systems_oem_revenue":"$0.3 million"}},"named_entities":{"people":[{"name":"Ben Shannon","role":"Media Contact, ICR Healthcare"},{"name":"Mike Cavanaugh","role":"Investor Contact, ICR Healthcare"}],"products":["Nanox.ARC X","Nanox.AI Bone Solution","Nanox.ARC","Nanox.CLOUD","Nanox.MARKETPLACE","USARAD"],"companies":[{"name":"NANO-X IMAGING LTD","ticker":"NNOX","relationship":"filer"},{"name":"Technologic s.r.l.","relationship":"distribution partner"},{"name":"Tecnologie Avanzate","relationship":"partner affiliate"},{"name":"Vaso Healthcare IT Inc. (now Nanox Health IT Inc.)","relationship":"consolidated subsidiary"}],"dollarAmounts":[{"amount":"$4.3 to $4.4 million","context":"preliminary Q3 2026 revenue"},{"amount":"$3.4 million","context":"Q3 2025 comparable revenue"},{"amount":"$3.1 million","context":"teleradiology revenue, flat YoY"},{"amount":"$0.3 million","context":"imaging systems and OEM revenue in Q3 2026"},{"amount":"$1.0 million","context":"AI and software revenue in Q3 2026"},{"amount":"$26.0 million","context":"preliminary cash, deposits and restricted deposits as of Sept 30, 2026"},{"amount":"$60.0 million","context":"cash and deposits as of Dec 31, 2025"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-16T20:05:07.170Z","global_importance":45,"audience_relevance":45,"importance_components":{"tickerTier":"small-cap","eventGravity":"going-concern disclosure with preliminary revenue","issuerAuthored":true,"retailFavoriteBoost":"NNOX has an elevated retail following"}},"durationMs":6805,"modelName":"glm-5.3-flashx"}}